IDTECK's surveillance technology finds application in healthcare sector
IDTECK is expected to provide high-level security with the SMART Card and biometrics systems
IDTECK, the foremost manufacturer in the areas of access control and time & attendance system, has been selected to provide the access system for the Osong Bio-Health Technopolis in Korea. Also known as the Osong complex, located in Cheongwon-gun, in Southern Korea, it is built to promote the development of the bio-health industry. The complex will house of six national institutions, which includes KFDA (Korea food & Drug Administration), KCDC (Korea Centre for Disease Control and Prevention), KHIDI (Korea Health Industry Development Institute) and internationally renowned bio-companies such as LG Life Sciences, CJ and TissueGene. 

This project was scheduled to kick off on June 2010. IDTECK access control system will be implemented throughout the site, where the six government-affiliated organisations will operate. IDTECK access control products are expected to provide high level security combined with user convenience by using the SMART Card and biometrics systems.

For more information, please visit the IDTECK website or send an e-mail.

In case you missed it

How National Agrarian University modernises campus access and mobility with Hikvision
How National Agrarian University modernises campus access and mobility with Hikvision

In a move to modernise campus operations and create a smoother experience for students and staff, Peru’s National Agrarian University has deployed a comprehensive Hikvision s...

Too many alerts, too little time: how AI is tackling control room fatigue
Too many alerts, too little time: how AI is tackling control room fatigue

Control room operators face a tricky and ever-growing list of responsibilities. Every day, they're expected to monitor dozens, sometimes hundreds, of camera feeds, identify suspici...

dormakaba Q1 2026/27: Net sales rise 5.2%
dormakaba Q1 2026/27: Net sales rise 5.2%

dormakaba generated net sales of CHF 702.9 million in the first quarter of financial year 2026/27 (1 July to 30 September 2026), with an organic net sales growth of 4.0%. While acq...